$ANAB
AnaptysBio Inc Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000137005318000037 Filed on August 07, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$5.000M	$0.00	$7.000M
YoY Change		-100.0%	19.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.000M	$3.830M	$2.350M
YoY Change	67.36%	62.98%	104.35%
% of Gross Profit
Research & Development	$17.88M	$10.58M	$7.205M
YoY Change	167.03%	46.88%	208.57%
% of Gross Profit
Depreciation & Amortization	$90.00K	$70.00K	$50.00K
YoY Change	80.0%	40.0%	-16.67%
% of Gross Profit
Operating Expenses	$21.89M	$14.42M	$9.555M
YoY Change	140.86%	50.86%	174.02%
Operating Profit	-$16.89M	-$14.42M	-$2.555M
YoY Change	85.84%	464.19%	-208.13%
Interest Expense	$400.0K	$436.0K	$439.0K
YoY Change	-11.5%	-0.68%	278.45%
% of Operating Profit
Other Income/Expense, Net	$929.0K	$797.0K	-$129.0K
YoY Change	-31066.67%	-717.83%	214.63%
Pretax Income	-$15.96M	-$13.62M	-$2.680M
YoY Change	75.56%	408.13%	-215.52%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.96M	-$13.62M	-$2.684M
YoY Change	75.56%	407.38%	-215.59%
Net Earnings / Revenue	-319.16%		-38.34%
Basic Earnings Per Share	-$0.66	-$0.57	-$0.13
Diluted Earnings Per Share	-$0.66	-$0.57	-$0.13
COMMON SHARES
Basic Shares Outstanding	24.04M shares	23.50M shares	20.27M shares
Diluted Shares Outstanding			20.27M shares

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$493.8M	$267.9M	$106.4M
YoY Change	326.72%	151.89%	110.2%
Cash & Equivalents	$293.4M	$57.06M	$30.75M
Short-Term Investments	$200.4M	$210.9M	$75.61M
Other Short-Term Assets	$4.000M	$3.800M	$3.900M
YoY Change	29.03%	-2.56%	333.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$503.0M	$271.8M	$115.8M
YoY Change	318.05%	134.63%	110.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.344M	$1.086M	$543.0K
YoY Change	161.99%	100.0%	8.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$18.60M	$32.70M	$13.90M
YoY Change	1760.0%	135.25%
Other Assets	$79.00K	$322.0K	$100.0K
YoY Change	-21.0%	222.0%	-96.55%
Total Long-Term Assets	$20.10M	$34.20M	$14.56M
YoY Change	1142.21%	134.86%	328.26%
TOTAL ASSETS
Total Short-Term Assets	$503.0M	$271.8M	$115.8M
Total Long-Term Assets	$20.10M	$34.20M	$14.56M
Total Assets	$523.1M	$306.0M	$130.4M
YoY Change	328.98%	134.66%	122.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.180M	$4.426M	$3.724M
YoY Change	141.69%	18.85%	77.33%
Accrued Expenses	$7.145M	$4.837M	$3.230M
YoY Change	98.25%	49.75%	11.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.500M	$7.500M	$3.100M
YoY Change	50.0%	141.94%	210.0%
Total Short-Term Liabilities	$20.87M	$16.79M	$10.08M
YoY Change	86.8%	66.58%	14.53%
LONG-TERM LIABILITIES
Long-Term Debt	$2.400M	$4.100M	$11.00M
YoY Change	-74.19%	-62.73%	175.0%
Other Long-Term Liabilities	$200.0K	$100.0K	$200.0K
YoY Change	100.0%	-50.0%	-84.62%
Total Long-Term Liabilities	$2.600M	$4.200M	$11.20M
YoY Change	-72.34%	-62.5%	111.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.87M	$16.79M	$10.08M
Total Long-Term Liabilities	$2.600M	$4.200M	$11.20M
Total Liabilities	$23.40M	$21.00M	$21.20M
YoY Change	13.59%	-0.94%	50.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.7M	-$113.7M	-$69.10M
YoY Change	65.85%	64.54%
Common Stock	$27.00K	$24.00K	$20.00K
YoY Change	35.0%	20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$499.7M	$285.0M	$109.2M
YoY Change
Total Liabilities & Shareholders Equity	$523.1M	$306.0M	$130.4M
YoY Change	328.98%	134.66%	122.92%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$15.96M	-$13.62M	-$2.684M
YoY Change	75.56%	407.38%	-215.59%
Depreciation, Depletion And Amortization	$90.00K	$70.00K	$50.00K
YoY Change	80.0%	40.0%	-16.67%
Cash From Operating Activities	-$14.86M	-$8.880M	-$2.640M
YoY Change	282.01%	236.36%	-258.08%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$310.0K	-$60.00K
YoY Change	1500.0%	416.67%	500.0%
Acquisitions
YoY Change
Other Investing Activities	$24.94M	-$2.760M	-$62.35M
YoY Change	-5189.8%	-95.57%
Cash From Investing Activities	$24.62M	-$3.070M	-$62.42M
YoY Change	-5124.49%	-95.08%	624100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$227.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	226.6M	-480.0K	-930.0K
YoY Change	75433.33%	-48.39%	144.74%
NET CHANGE
Cash From Operating Activities	-14.86M	-8.880M	-2.640M
Cash From Investing Activities	24.62M	-3.070M	-62.42M
Cash From Financing Activities	226.6M	-480.0K	-930.0K
Net Change In Cash	236.4M	-12.43M	-65.99M
YoY Change	-5893.14%	-81.16%	-5255.47%
FREE CASH FLOW
Cash From Operating Activities	-$14.86M	-$8.880M	-$2.640M
Capital Expenditures	-$320.0K	-$310.0K	-$60.00K
Free Cash Flow	-$14.54M	-$8.570M	-$2.580M
YoY Change	275.71%	232.17%	-253.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2097000	USD
	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	0	USD
	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	1500000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2217000	shares
CY2017Q4	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2961000	USD
CY2018Q2	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2921000	USD
CY2018Q2	anab	Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions	27600000	USD
CY2017Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	1601000	USD
CY2018Q2	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	200000	USD
CY2018Q2	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	152000	USD
CY2017Q2	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	1438000	USD
	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	2304000	USD
CY2018Q2	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	2548000	USD
	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	4808000	USD
	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	4607000	USD
	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24036451	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO INC
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2323000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4426000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4875000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4837000	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	140000	USD
CY2018Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	128000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3978000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4073000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-426000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-677000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	393017000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399370000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2108000	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2542000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2576000	shares
CY2017Q4	us-gaap	Assets Assets	329364000	USD
CY2018Q2	us-gaap	Assets Assets	306017000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	252696000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	271819000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	679000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2350000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4403000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3832000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7779000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2100000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	246752000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	246075000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	167218000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	210852000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	75897000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	32730000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	194000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81189000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57057000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51292000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30812000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81249000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57117000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20480000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24132000	USD
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4992705	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23791000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24028504	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24029000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23791000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24028504	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24029000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2730000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14178000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13494000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28954000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	90000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1588000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1602000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M1D
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1225000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	1519000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1449000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2490000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1186000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	439000	USD
	us-gaap	Interest Expense InterestExpense	867000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	436000	USD
	us-gaap	Interest Expense InterestExpense	887000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	281000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	404000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1297000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2482000	USD
	us-gaap	Interest Paid InterestPaid	469000	USD
	us-gaap	Interest Paid InterestPaid	585000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329364000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	306017000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14090000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16790000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79766000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1860000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89506000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-916000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10740000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21356000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2684000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14119000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-13618000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28704000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-129000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1576000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	797000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1468000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6875000	USD
CY2018Q2	us-gaap	Notes Payable Current NotesPayableCurrent	7500000	USD
CY2017Q4	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	7553000	USD
CY2018Q2	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	4120000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	9555000	USD
	us-gaap	Operating Expenses OperatingExpenses	19543000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	14415000	USD
	us-gaap	Operating Expenses OperatingExpenses	30172000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2555000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12543000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14415000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3001000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	726000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	968000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30172000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	938000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	369000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	326000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	314000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	322000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-46000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-59000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	124000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-250000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-46000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-59000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	124000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-250000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	17000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	27000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-303000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-317000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	253000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-127000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1485000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	280000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	89353000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	90411000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	153000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	536000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	11520698	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	24784	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	57.47
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2688000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3758000	USD
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	194700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80213000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	90031000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	503000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1469000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1500000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	535000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	76000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4643000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5159000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1086000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3125000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7205000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15140000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10583000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22393000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85034000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113738000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113700000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7000000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7000000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1400654	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	961141	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	274457	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	128278000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425903	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2455234	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.03
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.50
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	105.48
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	87855000	USD
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	68.50
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	220342	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	307581000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	284979000	USD
CY2017Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1429
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	255000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20271000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17797000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23932000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23867000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of the Business </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities, and at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> have an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$113.7 million</font><font style="font-family:inherit;font-size:10pt;">. Through </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements, proceeds from our Term Loans as discussed in Note 5 below, and the issuance of convertible debt. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Public Offerings and Related Transactions</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">On January 31, 2017, we completed an initial public offering, or IPO, selling </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,750,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$15.00</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per share. Proceeds from our initial public offering net of underwriting discounts and commissions were </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$80.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, each of the following occurred in connection with the completion of the IPO on January 31, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of all outstanding shares of convertible preferred stock into </font><font style="font-family:inherit;font-size:10pt;">11,520,698</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock into warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the resultant reclassification of the warrant liability to additional paid-in capital.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, we amended and restated our certificate of incorporation to effect a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of every outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the reverse stock split. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Public Offering </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 17, 2017, we completed an underwritten public offering selling </font><font style="font-family:inherit;font-size:10pt;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </font><font style="font-family:inherit;font-size:10pt;">$194.7 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions. As part of the underwritten public offering, on November 14, 2017, the underwriters exercised an additional </font><font style="font-family:inherit;font-size:10pt;">271,380</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a discounted price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$17.6 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001370053-18-000037-index-headers.html	Edgar Link	pending
0001370053-18-000037-index.html	Edgar Link	pending
0001370053-18-000037.txt	Edgar Link	pending
0001370053-18-000037-xbrl.zip	Edgar Link	pending
anab-20180630.xml	Edgar Link	completed
anab-20180630.xsd	Edgar Link	pending
anab-20180630_cal.xml	Edgar Link	unprocessable
anab-20180630_def.xml	Edgar Link	unprocessable
anab-20180630_lab.xml	Edgar Link	unprocessable
anab-20180630_pre.xml	Edgar Link	unprocessable
anab-63018x10q.htm	Edgar Link	pending
anab-63018x10qxexx311.htm	Edgar Link	pending
anab-63018x10qxexx312.htm	Edgar Link	pending
anab-63018x10qxexx321.htm	Edgar Link	pending
anab-63018x10qxexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
investorrightsagramend.htm	Edgar Link	pending
pipelinebarchart1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
siteplan1.jpg	Edgar Link	pending
subleaseagreement.htm	Edgar Link	pending
tenantimprovement1.jpg	Edgar Link	pending
tenantimprovement2.jpg	Edgar Link	pending
tenantimprovement3.jpg	Edgar Link	pending
tenantimprovement4.jpg	Edgar Link	pending
tenantnotice1.jpg	Edgar Link	pending
tenantnotice2.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
AnaptysBio Inc Stock $anab

2018 Q3 Form 10-Q Financial Statement

#000137005318000037 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB AnaptysBio Inc Stock $anab

2018 Q3 Form 10-Q Financial Statement

#000137005318000037 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
AnaptysBio Inc Stock $anab